Articles Referencing XBI

Zacks.com

Biotechnology ETF Investing 101 - ETF News And Commentary

With ever-increasing health care spending and insatiable demand for new drugs, the biotechnology sector looks poised for good growth going forward. Furthermore, the U.S. biotech... Read >>

David Moenning

Acorda Therapeutics, Inc. (ACOR): Today's Most Compelling Stock Buy

  SoTM Bull's Eye Report - Today's Most Compelling Buy Monday, May 13, 2013 At StateoftheMarkets.com , we strive to "own the best and ignore the... Read >>

Benzinga

S&P Highlights Biotech ETFs

Bolstered by an accommodating Food & Drug Administration and promising recent clinical results for drugs aimed at treating conditions such as hepatitis C and multiple... Read >>

David Moenning

Pharmacyclics Inc. (PCYC): Today's Most Compelling Stock Buy

  SoTM Bull's Eye Report - Today's Most Compelling Buy Tuesday, May 7, 2013 At StateoftheMarkets.com , we strive to "own the best and ignore the... Read >>

David Moenning

Polycyclics Inc. (PCYC): Today's Most Compelling Stock Pick

  SoTM Bull's Eye Report - Today's Most Compelling Buy Friday, April 26, 2013 At StateoftheMarkets.com , we strive to "own the best and ignore the... Read >>

David Moenning

United Therapeutics Corp. (UTHR): Today's Most Compelling Stock Buy

  SoTM Bull's Eye Report - Today's Most Compelling Buy Monday, April 22, 2013 At StateoftheMarkets.com , we strive to "own the best and ignore the... Read >>

Benzinga

Biotech Mutual Funds Show ETFs Are The Place to Be

In March, we compared a a popular energy sector ETF and a comparable mutual fund with the idea being to figure out when relevant factors are considered, which vehicle is best for investors. ... Read >>

Benzinga

Vertex News Lifts Biotech ETFs

Shares of biotechnology firm Vertex Pharmaceuticals (NASDAQ: VRTX ) are soaring by more than 55 percent early Friday and have touched a new all-time high after the company announced late... Read >>

Zacks.com

3 Sector ETFs Surviving This Slump - ETF News And Commentary

It has definitely been a rough couple of days in the stock market. The S&P 500, as represented by SPY , has lost about 2.3% in the past five days, a shift in the trends that investors... Read >>

Benzinga

Under The Hood: An Unheralded Biotech ETF

Another day, another set of fresh all-time highs for the major biotechnology ETFs . Biotech investors were treated to the same feat in late March , but as health care has continued to be a... Read >>

Benzinga

Biotech Breakout Boosting ETFs

The four horsemen of the biotechnology - Amgen (NASDAQ: AMGN ), Biogen Idec (NASDAQ: BIIB ), Celgene (NASDAQ: CELG ) and Gilead Sciences (NASDAQ: GILD ) - all hit new 52-week highs... Read >>

Benzinga

Exploring No Man's Land ETFs

First, the phrase "no man's land ETFs " needs to be defined and explained. To be sure, it is not as negative as some might be thinking. Actually, it is not negative at all.... Read >>

David Moenning

Regeneron Pharmaceuticals Inc (REGN): Today's Most Compelling Buy

  SoTM Bull's Eye Report - Today's Most Compelling Buy Thursday, March 14, 2013 At StateoftheMarkets.com , we strive to "own the best and ignore the... Read >>

Benzinga

If Stocks Keep Soaring, Get to Know These Leveraged ETFs

Another day, another intrday record for the Dow Jones Industrial Average. Buoyed by a stronger-than-expected February jobs report, U.S. stocks continue to grind higher. Friday's action is of... Read >>

NASDAQ.com News

Spectrum Pharmaceuticals, Inc. (SPPI) Ex-Dividend Date Scheduled for December 18, 2012

Spectrum Pharmaceuticals, Inc. ( SPPI ) has announced an ex-dividend date of December 18, 2012 and a cash dividend payment of $0.15 per share scheduled for December 28, 2012. Shareholders who... Read >>

Displaying 1-15 of 34
<< first < previous 1 2 3 next > last >>